| Literature DB >> 25905035 |
Tamaki Kurosawa1, Atsushi Yamada2, Masamichi Takami3, Dai Suzuki2, Yoshiro Saito4, Katsuhiro Hiranuma5, Takuya Enomoto6, Naoko Morimura7, Matsuo Yamamoto8, Takehiko Iijima9, Tatsuo Shirota10, Hiroyuki Itabe11, Ryutaro Kamijo2.
Abstract
Nephronectin (Npnt), also called POEM, is an extracellular matrix protein considered to play critical roles as an adhesion molecule in the development and functions of various tissues, such as the kidneys, liver, and bones. In the present study, we examined the molecular mechanism of Npnt gene expression and found that oncostatin M (OSM) strongly inhibited Npnt mRNA expression in MC3T3-E1 cells from a mouse osteoblastic cell line. OSM also induced a decrease in Npnt expression in both time- and dose-dependent manners via both the JAK/STAT and MAPK pathways. In addition, OSM-induced inhibition of osteoblast differentiation was recovered by over-expression of Npnt. These results suggest that OSM inhibits Npnt expression via the JAK/STAT and MAPK pathways, while down-regulation of Npnt by OSM influences inhibition of osteoblast differentiation.Entities:
Keywords: BMP-2, bone morphogenetic protein-2; ERK, extracellular signal-regulated kinase; JAK, janus kinase; JAK/STAT; JNK, c-Jun N-terminal kinase; MAM, meprin, A5 protein, and receptor protein-tyrosine phosphatase μ; MAPK; MAPK, mitogen-activated protein kinase; MEF2, myocyte enhancer-binding factor 2A; Nephronectin; Npnt, nephronectin; OSM, oncostatin M; OSMR, OSM receptor; Oncostatin M; STAT, signal transducer and activator of transcription; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α
Year: 2015 PMID: 25905035 PMCID: PMC4404411 DOI: 10.1016/j.fob.2015.04.001
Source DB: PubMed Journal: FEBS Open Bio ISSN: 2211-5463 Impact factor: 2.693
Fig. 1Reduction of Npnt mRNA expression by OSM. MC3T3-E1 cells were treated with 100 ng/ml of OSM, LIF, IL-6, or IL-11 for 24 h. Total cellular RNA was extracted, and mRNA levels for Npnt and Gapdh were examined by real-time PCR analysis. Results are shown as the mean ± SD from 3 samples as compared to the level at 0 ng/ml (without cytokine treatment). ∗∗P < 0.01, ∗P < 0.05, Student’s t test relative to the level without cytokine treatment.
Fig. 2Dose- and time-dependent effects of OSM on Npnt mRNA expression. (A) Dose-dependent effects of OSM on Npnt mRNA expression. MC3T3-E1 cells were treated with 0, 0.1, 1, 10, or 100 ng/ml of OSM for 24 h. Results are shown as the mean ± SD from 3 samples as compared to the level with 0 ng/ml of OSM. ∗∗P < 0.01, ANOVA relative to the level with 0 ng/ml of OSM. §§P < 0.01, ANOVA relative to the level with 0.1 ng/ml of OSM. (B) Time course analysis of effects of OSM on Npnt mRNA expression. MC3T3-E1 cells were treated with 10 ng/ml of OSM for 3, 6, 9, 12, or 24 h. Total cellular RNA was extracted, and mRNA levels for Npnt and Gapdh were examined using real-time PCR analysis. Results are shown as the mean ± SD from 3 samples as compared to the level at 0 h. ∗∗P < 0.01, ∗P < 0.05, Student’s t test as compared to the level with 0 ng/ml of OSM at each time points.
Fig. 3Analysis of OSM signaling molecules. (A) RT-PCR analysis for presence of OSM receptor (Osmr) and gp130 in MC3T3-E1 cells. With the present primers, the size of the PCR products for Osmr and gp130 were 132 and 100 bp, respectively. (B) MC3T3-E1 cells were subjected to flow cytometry analysis for the presence of the OSM receptor (OSMR) on the cell surface. The black area shows MC3T3-E1 cells incubated with biotinylated anti-OSMR and FITC streptavidin. The gray area shows MC3T3-E1 cells incubated with biotinylated anti-rat IgG2b κ isotype and FITC streptavidin. All cells were found positive for the OSM receptor. (C) OSM-induced phosphorylation of STAT3 blocked by JAK inhibitor. MC3T3-E1 cells were pretreated with 10 μM of the JAK inhibitor for 1 h, then treated with 10 ng/ml of OSM for 15 min. Total cellular proteins were extracted, and used to determine levels of phosphorylated and total STAT3 [23]. (D) Inhibition of down-regulation of OSM-induced Npnt expression by JAK inhibitor. MC3T3-E1 cells were treated with 10 ng/ml of OSM and 10 μM of the JAK inhibitor for 24 h. Total cellular RNA was extracted, and mRNA levels for Npnt and Gapdh were examined using real-time PCR analysis. Results are shown as the mean ± SD from 3 samples as compared to the level with 0 ng/ml of OSM and the JAK inhibitor. ∗∗P < 0.01, Student’s t test relative to the level with 0 ng/ml of the JAK inhibitor.
Fig. 4Inhibition of Npnt expression by OSM is regulated by ERK1/2. MC3T3-E1 cells were treated with 10 ng/ml of OSM and MAPK inhibitors (+PD; 10 μM PD98059,+SB; 10 μM SB203580, or +SP; 10 μM SP600125) for 24 h. Total cellular RNA was extracted, and mRNAs for Npnt and Gapdh were examined using real-time PCR analysis. Results are shown as the mean ± SD from 6 samples as compared to the level with 0 ng/ml of OSM and the MAPK inhibitors. ∗∗P < 0.01, Student’s t test relative to the level without MAPK inhibitors.
Fig. 5Over-expression of Npnt recovers OSM-induced inhibition of osteoblast differentiation. Npnt expressed vector or empty vector transfected MC3T3-E1 cells were treated with BMP-2 (500 ng/ml) and with/without OSM (■ OSM (100 ng/ml) or □ no treatment), then alkaline phosphatase (ALP) activity was determined after 2 days of treatment. Results are shown as the mean ± SD from 6 samples as compared to the level in empty vector transfected MC3T3-E1 cells with 0 ng/ml of OSM. ∗∗P < 0.01, ∗P < 0.05, Student’s t test relative to level in empty vector transfected MC3T3-E1 cells.
Fig. 6OSM strongly inhibits Npnt gene expression via the JAK/STAT and MAPK signaling pathways, while OSM-induced inhibition of osteoblast differentiation is recovered by Npnt over-expression in MC3T3-E1. RGD; motif of Arg-Gly-Asp tripeptide.